Key result
Ginsenoside Rg1 lowers blood glucose and improves liver function in a T2D rat model.
Why the study?
The liver is primarily damaged in T2-DM patients, especially those with high blood lipid levels, and the hepatoprotective effects of ginsenoside Rg1 in T2-DM require investigation.
Does ginsenoside Rg1 improve glucose metabolism and liver injury in streptozotocin-induced type 2 diabetic rats?
Does ginsenoside Rg1 improve glucose metabolism and liver injury in streptozotocin-induced type 2 diabetic rats?
Ginsenoside Rg1 improves glucose metabolism and liver injury in a diabetic rat model, suggesting potential as an adjuvant therapy for T2DM with fatty liver disease.
Answers are grounded in this paper and cite their sources.
Preclinical rat data do not support clinical use; leaves open ginsenoside Rg1 efficacy and safety in human T2DM.
Type 2 diabetes mellitus (T2-DM) is a chronic metabolic disorder characterized by high blood glucose levels. T2-DM patients suffer from many complications, such as diabetic fatty liver and diabetic nephropathy. The liver, the pivotal organ involved in both glucose and lipid metabolism, is primarily damaged in T2-DM patients, especially in those with high levels of blood lipid. In this study, the hepatoprotective activity of ginsenoside Rg1 was investigated in a T2-DM rat model. The results revealed a potent hepatoprotective effect of ginsenoside Rg1. This effect was primarily mediated by the antiapoptotic effect, inhibition of JNK activity, and suppression of inflammation after ginsenoside Rg1 treatment. Ginsenoside Rg1 also lowered the blood glucose level and insulin resistance index in T2-DM rats. Moreover, the blood lipid profile (total cholesterol, triglycerides, and low-density lipoprotein cholesterol levels) and liver function (aspartate transaminase and alanine transaminase levels) improved after ginsenoside Rg1 treatment. The aforementioned hepatoprotective effects of ginsenoside Rg1 in the T2-DM rat model suggests its clinical potential as an adjuvant drug for T2-DM therapy, especially for T2-DM patients with fatty liver disease.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2017) studied Type 2 diabetes mellitus with liver injury. Ginsenoside Rg1 was evaluated on Hepatoprotective activity, glucose metabolism, and liver injury. Ginsenoside Rg1 demonstrated potent hepatoprotective effects, lowered blood glucose and insulin resistance, and improved lipid profiles and liver function in a type 2 diabetic rat model.
Synapse has enriched 10 related papers. Consider them for comparative context: